[Newly treated epilepsy: a French observational study]

S Dupont1, A-M Marion-Audibert, H Mechin

  • 1Unité d'Epileptologie, Clinique Neurologique Paul Castaigne, Hôpital de la Pitié-Salpêtrière, Paris, France.

Revue Neurologique
|March 7, 2006
PubMed

Insights

This study analyzed 2220 epilepsy patients receiving their first oral anti-epileptic treatment, finding valproic acid most prescribed. High recurrence risk and syndromic diagnosis influenced treatment initiation in this diverse patient group.

Area of Science:

  • Neurology
  • Clinical Pharmacology

Context:

  • Epilepsy management involves initiating oral anti-epileptic treatments (OAETs) for newly diagnosed or recurring seizures.
  • Understanding patient characteristics and treatment patterns is crucial for optimizing epilepsy care.
  • This study captures real-world data on first-time OAET prescriptions in a large patient cohort.

Purpose:

  • To characterize patients receiving their first oral anti-epileptic treatment.
  • To identify factors influencing the initiation of anti-epileptic drug therapy.
  • To describe diagnostic assessments and treatment choices in newly treated epilepsy patients.

Summary:

  • A cohort of 2220 epilepsy patients (adults and children) initiated on OAETs was studied.
  • Focal and generalized epilepsies were common, with a significant proportion experiencing a single seizure prior to treatment.
  • Valproic acid was the most frequently prescribed drug, favored for its efficacy and ease of use, with recurrence risk being a primary driver for treatment initiation.

Impact:

  • Provides valuable epidemiological and clinical insights into first-time epilepsy treatment in a large cohort.
  • Highlights the importance of diagnostic workup, including EEG and neuroimaging, in epilepsy management.
  • Informs clinical decision-making regarding treatment initiation and drug selection for epilepsy.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...